| Detailed information |
|---|
| CancerLivER ID | 2002 |
| Biomarker | EZH2 |
| Biomarker Name/Symbol (given in Publication) | EZH2 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential diagnostic marker for HCC and overexpressed in HCC v/s normal samples (validated in 3 datasets) |
| Experimental Condition | HCC v/s Normal |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated (1.5 fold) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 28977866 |
| Type of Biomarker | Diagnostic |
| Pathway | Cancer Pathways include regulation of cellular protein metabolic process (GO:0032268), apoptotic process (GO:0006915), regulation of intracellular signal transduction (GO:1902531), cell cycle (GO:0007049), cell cycle phase transition (GO:0044770), pathways in cancer (Hsa05200), signaling pathways re |
| Cohort | In GSE14520 dataset, 445 samples derived from HCC patients (225 tumor tissues and 220 non-cancerous tissues), for GSE6764, 45 samples ( 35 tumor tissues and 10 non- cancerous tissues). In addition, TCGA cohort have 84 HCC tumor samples and 42 paired adjcent non-cancer samples . Beside this, The norm |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2017 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |